紫杉醇联合顺铂治疗晚期乳腺癌临床观察

目的：观察紫杉醇联合顺铂（TP方案）治疗蒽环类耐药的复发转移性晚期乳腺癌的疗效与安全性。方法：从2005年6月-2008年6月以TP方案治疗蒽环类耐药的复发转移性晚期乳腺癌28例，紫杉醇135mg／m^2静滴，第1天；顺铂75mg／m^2静滴，第一天，21天为1周期，2个周期末评价近期疗效及安全性。结果：28例患者中CR1例（3．5％），PR13例（46．4％），SD8例（28．5％），PD6例（21．4％），有效率50％，不良反应主要是骨髓抑制，恶心、呕吐、脱发。结论：TP方案治疗蒽环类耐药的复发转移性晚期乳腺癌疗效可靠，不良反应可耐受，可作为蒽环类耐药的复发转移性晚期乳腺癌的化疗方案。

Clinical observation of paclitaxel and cisplatin in the treatment of advanced breast cancer

Objective：To observe the efficacy of paclitaxel and cisplatin（TP regimen） in the treatment of anthra- cycline - resistant metastatic recurrence breast cancer. Methods ： TP regimen was used in the treatment of 28 anthra- cycline- resistant metastatic recurrent patients with breast cancer, intravenous infusion of 135mg/m^2 paclitaxel, d1, cisplatin75mg/m^2 intravenous infusion were given d1 ,21 day for one cycle, after 2 cycles, evaluate the recent efficacy. Results：In 28 cases CR 1 （3.5%） ,PR 13（46.4% ） ,SD 8（28.5% ） ,PD 6（21.4% ） ,the main side effect were myelosuppression, nausea, vomiting and hair loss. Conclusion： The treatment of TP regimen to anthracycline - resistant metastatic recurrent breast cancer is effect and reliable, toxicity can be tolerated.